Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company is headquartered in Toronto, Canada.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-166.94M |
| Operating Margin | 0.00% |
| Return on Equity | -86.90% |
| Return on Assets | -44.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.05 |
| Price-to-Book | 3.93 |
| Price-to-Sales (TTM) | 16436.36 |
| EV/Revenue | 11762.75 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $73.06M |
| Float | $58.56M |
| % Insiders | 14.03% |
| % Institutions | 41.26% |
Volatility is currently expanding
Helus Pharma, formerly known as Cybin NASDAQ: HELP, outlined its late-stage development plans for HLP-003 in adjunctive major depressive disorder (MDD) and discussed its broader pipeline of serotonergic agonists during TD Cowen's Novel Mechanisms in Neuropsychiatry virtual summit.
TORONTO, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the voting results for each of the matters presented at the Company's annual and special meeting of shareholders held on September 22, 2026 (the “Meeting”). There were 107 shareholders represented in person or by proxy at the Meeting holding 46,452,598 common shares, representing 63.58% of Helus's total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Meeting are set out below.
Cybin Inc. (HELP) Shareholder/Analyst Call Prepared Remarks Transcript
Cybin NASDAQ: HELP, doing business as Helus Pharma, held its Annual General and Special Meeting of Shareholders, where shareholders were asked to consider resolutions related to the company's auditor, board size, corporate name and director elections.
CEO Michael Halstead to participate in a fireside chat on September 23, 2026 at 9:00 a.m. EDT CEO Michael Halstead to participate in a fireside chat on September 23, 2026 at 9:00 a.m. EDT
Poster presentations further characterize clinical profile of HLP003 and Phase 3 PARADIGM program evaluating HLP003 as a potential adjunctive treatment for major depressive disorder (“MDD”) NEW YORK and TORONTO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today announced the presentation of four posters evaluating HLP003, an investigational oral deuterated psilocin analog being developed as an adjunctive treatment for MDD, at Psych Congress 2026, September 15–19, 2026, at the Ernest N.
Cybin NASDAQ: HELP executives outlined plans for its late-stage depression program, including an expected fourth-quarter Phase 3 data readout for HLP003, during H.C. Wainwright's 28th Annual Global Investment Conference.
Helus Pharma Chief Executive Officer Michael Halstead said the company expects a pivotal Phase III readout for its HLP003 program in adjunctive major depressive disorder in the fourth quarter, describing the data as a key near-term catalyst for the company's mental health treatment pipeline.
CEO Michael Halstead to participate in a fireside chat on Wednesday, September 16, 2026 at 8:30 a.m. EDT. CEO Michael Halstead to participate in a fireside chat on Wednesday, September 16, 2026 at 8:30 a.m. EDT.
CEO Michael Halstead to participate in a fireside chat on Monday, September 14, 2026 at 9:00 a.m. EDT CEO Michael Halstead to participate in a fireside chat on Monday, September 14, 2026 at 9:00 a.m. EDT
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on HELP and any ticker you trade — then tracks every position and per-strategy win rate.
